The lipid-reactive oxygen species phenotype of breast cancer. Raman spectroscopy and mapping, PCA and PLSDA for invasive ductal carcinoma and invasive lobular carcinoma. Molecular tumorigenic mechanisms beyond Warburg effect

The Analyst ◽  
2015 ◽  
Vol 140 (7) ◽  
pp. 2121-2133 ◽  
Author(s):  
Jakub Surmacki ◽  
Beata Brozek-Pluska ◽  
Radzislaw Kordek ◽  
Halina Abramczyk
Keyword(s):  
Breast Cancer ◽  
Reactive Oxygen Species ◽  
Raman Spectroscopy ◽  
Cancer Diagnosis ◽  
Warburg Effect ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Breast Cancer Diagnosis ◽  
Oxygen Species ◽  
Relevant Level

The paper demonstrates that Raman imaging has reached a clinically relevant level in regard to breast cancer diagnosis applications.

Raman Spectroscopy and Fluorescence Photon Migration for Breast Cancer Diagnosis and Imaging

1998 ◽  
Vol 67 (1) ◽  
pp. 15-22 ◽  
Author(s):  
Ramasamy Manoharan ◽  
Karen Shafer ◽  
Lev Perelman ◽  
Jun Wu ◽  
Kun Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Raman Spectroscopy ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Photon Migration ◽  
Fluorescence Photon

scholarly journals The Clinical Application of Raman Spectroscopy for Breast Cancer Detection

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Pin Gao ◽  
Bing Han ◽  
Ye Du ◽  
Gang Zhao ◽  
Zhigang Yu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Raman Spectroscopy ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Surface Enhanced Raman Spectroscopy ◽  
Cellular Level ◽  
Clinical Tool ◽  
Normal Tissues ◽  
Surface Enhanced Raman

Raman spectroscopy has been widely used as an important clinical tool for real-time in vivo cancer diagnosis. Raman information can be obtained from whole organisms and tissues, at the cellular level and at the biomolecular level. The aim of this paper is to review the newest developments of Raman spectroscopy in the field of breast cancer diagnosis and treatment. Raman spectroscopy can distinguish malignant tissues from noncancerous/normal tissues and can assess tumor margins or sentinel lymph nodes during an operation. At the cellular level, Raman spectra can be used to monitor the intracellular processes occurring in blood circulation. At the biomolecular level, surface-enhanced Raman spectroscopy techniques may help detect the biomarker on the tumor surface as well as evaluate the efficacy of anticancer drugs. Furthermore, Raman images reveal an inhomogeneous distribution of different compounds, especially proteins, lipids, microcalcifications, and their metabolic products, in cancerous breast tissues. Information about these compounds may further our understanding of the mechanisms of breast cancer.

scholarly journals Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects

2021 ◽  
Author(s):  
Katie Hanna ◽  
Emma Krzoska ◽  
Abeer M. Shaaban ◽  
David Muirhead ◽  
Rasha Abu-Eid ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Raman Spectroscopy ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Future Prospects

In vivo Raman spectroscopy for breast cancer: diagnosis in animal model

2008 ◽  
Author(s):  
R. Bitar ◽  
M. A. Martins ◽  
D. Ribeiro ◽  
C. Carvalho ◽  
E. A. P. Santos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Raman Spectroscopy ◽  
Animal Model ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
In Vivo Raman Spectroscopy

Primary gynecological neoplasms and clinical outcomes in patients diagnosed with breast carcinoma

2006 ◽  
Vol 16 (Suppl 1) ◽  
pp. 118-122
Author(s):  
P. F. Escobar ◽  
R. Patrick ◽  
L. Rybicki ◽  
N. Al-Husaini ◽  
C. M. Michener ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcomes ◽  
Cancer Diagnosis ◽  
Ductal Carcinoma ◽  
Bilateral Breast Cancer ◽  
Breast Cancer Diagnosis ◽  
Rank Test ◽  
Cancer Data ◽  
Synchronous Bilateral Breast Cancer ◽  
Gynecological Neoplasms

The purpose of this study was to quantify and describe nonmammary neoplasms (n-MN), particularly gynecological neoplasms, in a patient population previously diagnosed with breast cancer. Data were collected prospectively in our institutional review board–approved registry for patients diagnosed with infiltrating breast cancer or ductal carcinoma in situ. Patients who developed a second, n-MN were identified; neoplastic site, time to development after breast cancer, and clinical outcomes were recorded. FIGO stage was recorded for patients who developed a gynecological neoplasm. Synchronous bilateral breast cancer was defined as a second, contralateral diagnosis made within 12 months of the first and, similarly, synchronous n-MN were defined as those identified within 1 year of a breast cancer diagnosis. Outcome curves were generated using the method of Kaplan and Meier, and compared using the log-rank test. Of 4126 patients diagnosed with breast cancer, 3% developed a n-MN, the majority of which were nongynecological and asynchronous to the initial breast cancer diagnosis. Three percent of patients diagnosed with breast cancer were diagnosed with a second, n-MN. Among patients who developed a n-MN, most developed a nongynecological cancer more than 1 year after the initial breast cancer diagnosis, and their outcomes were significantly worse than those patients who did not develop a n-MN.

From Femtosecond Dynamics to Breast Cancer Diagnosis by Raman Spectroscopy

2007 ◽  
Author(s):  
H. Abramczyk ◽  
I. Placek ◽  
B. Brożek-Płuska ◽  
K. Kurczewski ◽  
Z. Morawiec ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Raman Spectroscopy ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Femtosecond Dynamics

Raman spectroscopy: development of clinical applications for breast cancer diagnosis

2005 ◽  
Author(s):  
Maryann Fitzmaurice ◽  
Abigail A. Haka ◽  
Zoya Volynskaya ◽  
Jason T. Motz ◽  
Joseph A. Gardecki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Raman Spectroscopy ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Clinical Applications

scholarly journals Classification for breast cancer diagnosis with Raman spectroscopy

2014 ◽  
Vol 5 (7) ◽  
pp. 2435 ◽  
Author(s):  
Qingbo Li ◽  
Qishuo Gao ◽  
Guangjun Zhang
Keyword(s):  
Breast Cancer ◽  
Raman Spectroscopy ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis

scholarly journals Screening prior to Breast Cancer Diagnosis: The More Things Change, the More They Stay the Same

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Erica B. Friedman ◽  
Jennifer Chun ◽  
Freya Schnabel ◽  
Shira Schwartz ◽  
Sidney Law ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Ductal Carcinoma ◽  
Task Force ◽  
Treatment Options ◽  
Breast Cancer Diagnosis ◽  
Chi Square ◽  
Palpable Mass ◽  
Screening Guidelines ◽  
Increased Risk

Purpose. In November 2009, the U.S. Preventative Service Task Force (USPSTF) revised their breast cancer screening guidelines. We evaluated the pattern of screening subsequent to the altered guidelines in a cohort of women.Methods. Our database was queried for the following variables: age, race, method of diagnosis, mass palpability, screening frequency, histology, and stage. Statistical analyses were performed using Pearson’s chi-square and Fisher’s exact tests.Results. 1112 women were diagnosed with breast cancer from January 2010 to 2012. The median age at diagnosis was 60 years. Most cancers were detected on mammography (61%). The majority of patients had invasive ductal carcinoma (59%), stage 0 (23%), and stage 1 (50%) cancers. The frequency of screening did not change significantly over time (P=0.30). However, nonregular screeners had an increased risk of being diagnosed with later stage breast cancer (P<0.001) and were more likely to present with a palpable mass compared to regular screeners (56% versus 21%;P<0.001).Conclusions. In our study, screening behavior did not significantly change in the years following the USPSTF guidelines. These results suggest that women who are not screened annually are at increased risk of a delay in breast cancer diagnosis, which may impact treatment options and outcomes.

Sign in / Sign up

Export Citation Format

Share Document